Trending

oncolytic virus

Sillajen explains Pexa-Vec trial failure – it was the rescue meds

Sillajen explains Pexa-Vec trial failure – it was the rescue meds

South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase

X

Sillajen explains Pexa-Vec trial failure – it was the rescue meds

https://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/

Immunotherapy arms race latest: Merck buys Viralytics for $394m

Immunotherapy arms race latest: Merck buys Viralytics for $394m

Big pharma pays 160% premium for Australian biotech

X

Immunotherapy arms race latest: Merck buys Viralytics for $394m

https://pharmaphorum.com/news/merck-co-buy-viralytics-cancer-killing-virus-394m/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com